DERMATOMYOSITIS (DM)

Clinical trials for DERMATOMYOSITIS (DM) explained in plain language.

Never miss a new study

Get alerted when new DERMATOMYOSITIS (DM) trials appear

Sign up with your email to follow new studies for DERMATOMYOSITIS (DM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 2 Not yet recruiting 1 Not yet finished but already full! 2

Can engineered immune cells tame stubborn autoimmune diseases?

Disease control Not yet recruiting

This phase 1 trial tests an experimental cell therapy called LMY-922 (BAFF CAR-T cells) in people aged 16 to 75 with refractory autoimmune diseases, including rheumatoid arthritis, lupus, dermatomyositis, and systemic sclerosis. The therapy uses donor immune cells engineered to t…

Matched conditions: DERMATOMYOSITIS (DM)

Phase: PHASE1 • Sponsor: Luminary Therapeutics • Aim: Disease control

Last updated Jul 30, 2026 00:00 UTC

DERMATOMYOSITIS (DM)

Get alerted when new DERMATOMYOSITIS (DM) trials appear

Can engineered immune cells tame stubborn autoimmune diseases?